Identification and structure - Activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms

Journal of Medicinal Chemistry

Volumn 52, Issue 23, 2009, Pages 7544-7569

  Jain, Nareshkumar ^a   Xu, Jiayi ^a   Kanojia, Ramesh M ^a   Du, Fuyong ^a   Guo, Jian Zhong ^a   Pacia, Emmanuel ^a   Lai, Muh Tsann ^a   Musto, Amy ^a   Allan, George ^a   Reuman, Michael ^a   Li, Xun ^a   Hahn, DoWon ^a   Cousineau, Martin ^a   Peng, Sean ^a   Ritchie, David ^a   Russell, Ronald ^a   Lundeen, Scott ^a   Sui, Zhihua ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 [4 (2,8 DIMETHOXY 11,12 DIHYDRO 5H 6,13 DIOXABENZO[3,4]CYCLOHEPTA[1,2 A]NAPHTHALEN 5 YL)PHENOXY]ETHYL]PIPERIDINE; 5 [4 (2 AZEPAN 1 YLETHOXY)PHENY] 11,12 DIHYDRO 5H 6,13 DIOXABENZO[3,4]CYCLOHEPTA[1,2 A]NAPHTHALEN 2,8 DIOL; 5 [4 (2 AZEPAN 1 YLETHOXY)PHENYL] 11,12 DIHYDRO 5H 6,13 DIOXABENZO[3,4]CYCLOHEPTA[1,2 A]NAPHTHALEN 2 OL; 5 [4 (2 AZEPAN 1 YLETHOXY)PHENYL] 11,12 DIHYDRO 5H 6,13 DIOXABENZO[3,4]CYCLOHEPTA[1,2 A]NAPHTHALEN 8 OL; 5 [4 (2 AZEPAN 1 YLETHOXY)PHENYL] 8 FLUORO 11,12 DIHYDRO 5H 6,13 DIOXABENZO[3,4]CYCLOHEPTA[1,2 A]NAPHTHALEN 2 OL; 5 [4 (2 DIETHYLAMINOETHOXY)PHENYL] 11,12 DIHYDRO 5H 6,13 DIOXABENZO [3,4]CYCLOHEPTA[1,2 A]NAPHTHALEN 2,8 DIOL; 5 [4 (2 DIISOPROPYLAMINOETHOXY)PHENYL] 11,12 DIHYDRO 5H 6,13 DIOXABENZO[3,4]CYCLOHEPTA[1,2 A]NAPHTHALEN 2,8 DIOL; 5 [4 (2 DIMETHYLAMINOETHOXY)PHENYL] 11,12 DIHYDRO 5H 6,13 DIOXABENZO[3,4]CYCLOHEPTA[1,2 A]NAPHTHALEN 2 OL; 5 [4 (2 DIMETHYLAMINOETHOXY)PHENYL] 11,12 DIHYDRO 5H 6,13 DIOXABENZO[3,4]CYCLOHEPTA[1,2 A]NAPHTHALEN 2,8 DIOL; 5 [4 (2 DIMETHYLAMINOETHOXY)PHENYL] 11,12 DIHYDRO 5H 6,13 DIOXABENZO[3,4]CYCLOHEPTA[1,2 A]NAPHTHALEN 8 OL; 5 [4 (2 MORPHOLIN 4 YLETHOXY)PHENYL] 11,12 DIHYDRO 5H 6,13 DIOXABENZO[3,4]CYCLOHEPTA[1,2 A]NAPHTHALEN 2,8 DIOL; 5 [4 (2 PIPERIDIN 1 YLETHOXY)PHENYL] 11,12 DIHYDRO 5H 6,13 DIOXABENZO[3,4]CYCLOHEPTA[1,2 A]NAPHTHALEN 2 OL; 5 [4 (2 PYRROLIDIN 1 YLETHOXY)PHENYL] 11,12 DIHYDRO 5H 6,13 DIOXABENZO[3,4]CYCLOHEPTA[1,2 A]NAPHTHALEN 2,8 DIOL; 5 [4 (3 HYDROXYPROPOXY)PHENYL] 11,12 DIHYDRO 5H 6,13 DIOXABENZO[3,4]CYCLOHEPTA[1,2 A]NAPHTHALEN 2,8 DIOL; 8 METHOXY 5 [4 (2 PIPERIDIN 1 YLETHOXY)PHENYL] 11,12 DIHYDRO 5H 6,13 DIOXABENZO[3,4]CYCLOHEPTA[1,2 A]NAPHTHALEN 2 OL; [4 (2 PIPERIDIN 1 YLETHOXY)PHENYL] 11,12 DIHYDRO 5H 6,13 DIOXABENZO[3,4]CYCLOHEPTA[1,2 A]NAPHTHALEN 2,8 DIOL; ANTIESTROGEN; BENZOPYRANOBENZOXAPANE; BENZOXAZINE DERIVATIVE; ESTROGEN; ESTRONE; ETHINYLESTRADIOL; LIPID; METHYLCELLULOSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG POTENCY; DRUG STABILITY; ESTROGEN ACTIVITY; FEMALE; HOT FLUSH; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID BLOOD LEVEL; MENOPAUSAL SYNDROME; METABOLITE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; UTERUS; VAGINA; VAGINAL DRYNESS;

ANIMALS; BENZOPYRANS; BONE RESORPTION; CELL LINE, TUMOR; CHOLESTEROL; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; EPITHELIAL CELLS; FEMALE; HOT FLASHES; HUMANS; ORGAN SIZE; OVARIECTOMY; POSTMENOPAUSE; RATS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; UTERUS; VAGINA;

EID: 72549086337     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900146e     Document Type: Article

References (98)

1. For recent reviews, see the following. (a) Jordan, V. C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. Receptor interactions. J. Med. Chem. 2003, 46, 883-908.
2. (b) Jordan, V. C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. Clinical considerations and new agents. J. Med. Chem. 2003, 46, 1081-1111.
3. (c) Riggs, B. L.; Hartmann, L. C. Selective estrogen-receptor modulators. Mechanisms of action and application to clinical practice. N. Engl. J. Med. 2003, 348, 618-629.
4. (d) Freedman, R. R. Physiology of hot flashes. Am. J. Hum. Biol. 2001, 13, 454-464.
5. (e) Johnson, K. A. The SERM of my dreams. J. Clin. Endocrinol. Metab. 2006, 91 (10), 3754-3756.
6. (f) Jordan, V. C. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discovery 2003, 2, 205-213.
7. (g) Ariazi, E. A.; Ariazi, J. L.; Cordera, F.; Jordan, V. C. Estrogen receptors as therapeutic targets in breast cancer. Curr. Top. Med.Chem. 2006, 6, 181-202.
8. (h) Rossouw, J. E.; Anderson, G. L.; Prentice, R. L.; LaCroix, A. Z.; Kooperberg, C.; Stefanick, M. L.; Jackson, R. D.; Beresford, S. A.; Howard, B. V.; Johnson, K. C.; Kotchen, J. M.; Ockene, J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, J. Am. Med. Assoc. 2002, 288, 321-333.
9. (i) Vogelvang, T. E.; van der Mooren, M. J.; Mijatovic, V.; Kenemans, P. Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women. Drugs 2006, 66, 191-221. (Pubitemid 43213903)
10. For recent reports, see the following. Shanafelt, T. D.; Barton, D. L.; Adjei, A. A.; Loprinzi, C. L. Pathphysiology and treatment of hot flashes. Mayo Clin. Proc. 2002, 77, 1207-1218.
11. (a) Simunic, V.; Banovic, I.; Ciglar, S.; Jeren, L.; Pavicic Baldani, D.; Sprem, M. Local estrogen treatment in patients with urogenital symptoms. Int. J. Gynecol. Obstet. 2003, 82 (2), 187-197.
12. (b) Miller, C. P. SERMs: evolutionary chemistry, revolutionary biology. Curr. Pharm. Des. 2002, 8 (23), 2089-2111.
13. (c) Kenemans, P.; Speroff, L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005, 51 (1), 21-28.
14. (d) Oskay, U. Y.; Beji, N. K.; Yalcin, O. A study on urogenital complaints of postmenopausal women aged 50 and over. Acta Obstet. Gynecol. Scand. 2005, 84 (1), 72-78.
15. (e) Bachmann, G. Urogenital ageing: an old problem newly recognized. Maturitas 1995, 22 (Suppl.), S1-S5. (Pubitemid 26021025)
16. (a) Seibel, M. M.; Freedman, R. R. Physiology of hot flashes. Am. J. Hum. Biol. 2001, 13, 454-464.
17. (b) Plouffe, L., Jr.; Facoq, C. M. Selective estrogen receptor modulators (SERMs) in clinical practice. J. Soc. Gynecol. Invest. 2000, 7, No. S38-S46.
18. (a) Hulley, S.; Grady, D.; Bush, T.; et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, J. Am. Med. Assoc. 1998, 280, 605-613.
19. (b) Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy. Lancet 1997, 350, 1047-1059.
20. (c) Gauthier, S.; Cloutier, J.; Dory, Y. L.; Favre, A.; Mailhot, J.; Ouellet, C.; Schwerdtfeger, A.; Merand, Y.; Martel, C.; Simard, J.; Labrie, F. Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. J. Enzyme Inhib. Med. Chem. 2005, 20 (2), 165-177.
21. (d) Grese, T. A.; Pennington, L. D.; Sluka, J. P.; Adrian, M. D.; Cole, H. W.; Fuson, T. R.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Shetler, P. K.; Short, L. L.; Venugopalan, M.; Yang, N. N.; Sato, M.; Glasebrook, A. L.; Bryant, H. U. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators. J. Med. Chem. 1998, 41, 1272-1283.
22. (e) Kim, S.;Wu, J.,; Birzin, E. T.; Frisch, K.; Chan,W.; Pai, L.; Yang, Y.; Mosley, R. T.; Fitzgerald, M. D.; Sharma, N.; Dahllund, J.; Thorsell, A.; DiNinno, F.; Rohrer, S. R.; Schaeffer, J. M.; Hammond, M. L. Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor modulators. J. Med. Chem. 2004, 47, 2171-2175.
23. (f)Wallace, O. B.; Lauwers, K. S.; Jones, S. A.; Dodge, J. A. Tetrahydroquinolinebased selective estrogen receptor modulators (SERMs). Bioorg. Med. Chem. Lett. 2003, 13, 1907-1910.
24. (g) Schmidt, J. M.; Tremblay, G. B.; Plastina, M. A.; Ma, F.; Bhal, S.; Feher, M.; Dunn-Dufault, R.; Redden, P. R. Bioorg. Med. Chem. 2005, 13, 1819-1828.
25. (h) Richardson, T. I.; Frank, S. A.; Wang, M.; Clarke, C. A.; Jones, S. A.; Ying, B. P.; Kohlman, D. T.; Wallace, O. B.; Shepherd, T. A.; Dally, R. D.; Palkowitz, A. D.; Geiser, A. G.; Bryant, H. U.; Henck, J. W.; Cohen, I. R.; Rudmann, D. G.; McCann, D. J.; Coutant, D. E.; Oldham, S. W.; Hummel, C.W.; Fong, K. C.; Hinklin, R.; Lewis, G.; Tian, H.; Dodge, J. A. Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety. Bioorg. Med. Chem. Lett. 2007, 17 (13), 3544-3549.
26. (i) Blizzard, T. A.; Morgan, J. D.; Chan,W.; Birzin, E. T.; Pai, L. Y.; Hayes, E. C.; DaSilva, C. A.; Mosley, R. T.; Yang, Y. T.; Rohrer, S. P.; Dininno, F.; Hammond, M. L. Estrogen receptor ligands. Part 14: application of novel antagonist side chains to existing platforms. Bioorg. Med. Chem. Lett. 2005, 1, 15 (23), 5124-5128.
27. (a) Davies, G. C.; Huster, M. W. J.; Lu, Y.; Plouffe, L., Jr.; Lakshmanan, M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet. Gynecol. 1999, 93, 558-565.
28. (b) Loprinzi, C. L.; Zahasky, K. M.; Slaoan, J. A.; Novotny, P. J.; Quella, S. K. Tamoxifen-induced hot flashes. Clin. Breast Cancer 2000, 1, 52-56.
29. (c) Komm, B. S.; Rusling, D. J.; Lyttle, C. R. Estrogen regulation of protein synthesis in the immature rat uterus: the analysis of proteins released into the medium during in vitro incubation. Endocrinology 1986, 118, 2411-2416.
30. (d) Komm, B. S.; Kharode,Y. P.; Bodine, P.V. N.; Harris, H. A.; Miller, C. P.; Lyttle, C. R. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005, 146 (9), 3999-4008. (Pubitemid 41175771)
31. (e) Lerner, L. J.; Hilf, R.; Turkheimer, A. R.; Michel, I.; Engel, S. L. Effects of hormone antagonists on morphological and biochemical changes induced by hormonal steroids in the immature rat uterus. Endocrinology 1966, 78, 111-124.
32. (f)Gabbard, R. B.; Hamer, L. F.; Segaloff, A. Structure-activity relationships of four 11-hydroxyestrones isomeric at the C-9 and C-11 positions. Steroids 1981, 37, 243-255. (Pubitemid 11107152)
33. (g) McKim, J. M., Jr.; Wilga, P. C.; Breslin, W. J.; Plotzke, K. P.; Gallavan, R. H.; Meeks, R. G. Potential estrogenic and antiestrogenic activity of the cyclic siloxane octamethylcyclotetrasiloxane (D4) and the linear siloxane hexamethyldisiloxane (HMDS) in immature rats using the uterotrophic assay. Toxicol. Sci. 2001, 63, 37-46.
34. (h) Ashby, J.; Odum, J.; Foster, J. R. Activity of raloxifene in immature and ovariectomized rat uterotrophic assays. Regul. Toxicol. Pharmacol. 1997, 25, 226-231.
35. (i) Ke, H. Z.; Brown, T. A.; Thompson, D. D. Lasofoxifene (CP-336,156), a novel selective estrogen receptor modulator, in preclinical studies. J. Am. Aging Assoc. 2002, 25, 87-99.
36. (j) Riggs, L.; Hartmann, L. C. Selective estrogen-receptor modulators. Mechanisms of action and application to clinical practice. N. Engl. J. Med. 2003, 348, 618-629.
37. (k) Komm, B. S.; Lyttle, C. R. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann. N.Y. Acad. Sci. 2001, 949, 317-326.
38. (l) Ashby, J.; Odum, J.; Foster, J. R. Activity of raloxifene in immature and ovariectomized rat uterotrophic assays. Toxicol. Pharmacol. 1997, 25, 226-231.
39. (m) Qu, Q.; Zheng, H.; Dahllund, J.; Laine, A.; Cockcroft, N.; Peng, Z.; Koskinen, M.; Hemminki, K.; Kangas, L.; Vaananen, K.; Harkonen, P. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000, 141, 809-820. (Pubitemid 32250507)
40. (n) Sato, M.; Turner, C. H.;Wang, T.; Adrian, M. D.; Rowley, E.; Bryant, H. U. J. LY353381 3 HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. Pharmacol. Exp. Ther. 1998, 287, 1-7.
41. (o) Geiser, A. G.; Hummel, C. W.; Draper, M. W.; Henck, J. W.; Cohen, I. R.; Rudmann, D. G.; Donnelly, K. B.; Adrian, M. D.; Shepherd, T. A.;Wallace, O. B.; McCann, D. J.; Oldham, S.W.; Bryant, H. U.; Sato, M.; Dodge, J. A. A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation. Endocrinology 2005, 146 (10), 4524-4535.
42. (p) Simpkins, J. W.; Katovich, M. J.; Song, I.-C. Chronic hyperprolactinemia reduces peripheral beta-adrenergic responsiveness in male rats. Life Sci. 1983, 32, 1957-1966.
43. (q) Katovich, M. J.; Simpkins, J.W.; Berglund, L. A.; O'Meara, J. Regional skin temperature changes in a rat model for the menopausal hot flush. Maturitas 1986, 8, 67-76. (Pubitemid 16140756)
44. (r) Merchenthaler, I.; Funkhouser, J. M.; Carver, J. M.; Lundeen, S. G.; Ghosh, K.; Winneker, R. C. The effect of estrogens and antiestrogens in a rat model for hot flush. Maturitas 1998, 30, 307-316.
45. (a) Jain, N.; Kanojia, R. M.; Xu, J.; Guo, J.; Pacia, E.; Lai, M.; Du, F.; Musto, A.; Allan, G.; Hahn, D.; Lundeen, S.; Sui, Z. Novel chromene-derived selective estrogen receptor modulators useful for alleviating hot flushes and vaginal dryness. J. Med. Chem. 2006, 49 (11), 3056-3059.
46. (b) Jain, N.; Xu, J.; Chen, N.; Sui, Z. A novel approach to the synthesis of 11,11-dimethyl-bisbenzopyran-5-ones. Tetrahedron Lett. 2006, 47 (2), 225-228.
47. (c) Xu, J.; Jain, N.; Sui, Z. Halogen-magnesium exchange of m- and p-iodo or bromo-arenes bearing ortho-directing groups through "ate complexes". Tetrahedron Lett. 2004, 45 (34), 6399-6402.
48. (d) Chen, N.; Jain, N.; Xu, J.; Reuman, M.; Li, X.; Russell, R. K.; Sui, Z. Synthesis of novel tetracyclic chromenes through carbanion chemistry of 4-methyl coumarins. Tetrahedron Lett. 2006, 47 (33), 5909-5913. (Pubitemid 44026607)
49. (e) Li, X.; Jain, N.; Russell, R. K.; Ma, R.; Branum, S.; Xu, J.; Sui, Z. Development of a scalable synthetic process for selective bromination of 4-methyl-3,7-substituted coumarins. Org. Process Res. Dev. 2006, 10 (2), 354-360.
50. (f) Kanojia, R. M.; Jain, N.; Xu, J.; Sui, Z. A facile synthesis of an unsymmetric benzopyranobenzopyran ring system. Tetrahedron Lett. 2004, 45 (30), 5837-5839. (Pubitemid 38968562)
51. (g) Li, X.; Reuman, M.; Russell, R. K.; Adams, R.; Ma, R.; Beish, S.; Branum, S.;Youells, S.; Roberts, J.; Jain, N.; Kanojia, R.; Sui, Z. Synthesis of tetracyclic heterocompounds as selective estrogen receptor modulators. Part 1. Process development for scale-up of 2,5,8-substituted 5,11-dihydrochromeno[4,3- c]chromene derivatives. Org. Process Res. Dev. 2007, 11 (3), 414-421.
52. (h) Li, X.; Reuman, M.; Russell, R. K.; Youells, S.; Beish, S.; Hu, Z.; Branum, S.; Jain, N.; Sui, Z. Synthesis of tetracyclic heterocompounds as selective estrogen receptor modulators. Part 2. Process improvement for scale-up of 2,5, 8-substituted 11,12-dihydro-5H-6,13-dioxabenzo[3,4]cyclohepta-[1,2- a]naphthalene derivatives. Org. Process Res. Dev. 2007, 11 (4), 731-738.
53. (i) Li, X.; Russell, R. K.; Horváth, A.; Jain, N.; Depré, D.; Ormerod, D.; Aelterman, W.; Sui, Z. Synthesis of tetracyclic heterocompounds as selective estrogen receptormodulators. Part 3.Development of an acid-catalyzed racemization process for (S)-2,8-(dimethoxy)- 5-{4-[2-(1-piperidinyl)ethoxy]- phenyl}-11,12-dihydro-5H-6,13 dioxabenzo[ 3,4]cyclohepta [1,2-a]naphthalene. Org. Process Res. Dev. 2009, 13, 102-105.
54. Kanojia, R. M.; Jain, N. F.; Ng, R.; Sui, Z.; Xu, J. Preparation of Tetracyclic Heterocycles as Selective Estrogen Receptor Modulators (SERMs). WO 2003053977, 2003; US 71997520031121, 2004.
55. (a) The absolute stereochemistry was determined by single X-ray crystallography.
56. (b) See Supporting Information for details.
57. (a) Allan, G. F.; Hutchins, A.; Clancy, J. An ultrahigh-throughput screening assay for estrogen receptor ligands. Anal. Biochem. 1999, 275, 243-247.
58. (b) Rufbin,V. N.; Ruenitz, P. C.; Boyd, J. L.; Boudinot, F. D.; Wiese, T. E. Characterization of selective estrogen receptor modulator (SERM) activity in two triarylethylene oxybutyric acids. Biochem. Pharmacol. 2002, 63, 1517-1525.
59. Wang, T. T.; Sathyamoorthy, N.; Phang, J. M. Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis 1996, 17, 271-275.
60. (a) Albert, J. L.; Sundstrom, S. A.; Lyttle, C. R. Estrogen regulation of placental alkaline phosphatase gene expression in a human endometrial adenocarcinoma cell line. Cancer Res. 1990, 50, 3306-3310.
61. (b) Holinka, C. F.; Hata, H.; Kuramoto, H.; Gurpide, E. Responses to estradiol in a human endometrial adenocarcinoma cell line (Ishikawa). J. Steroid Biochem. 1986, 24, 85-89. (Pubitemid 16047761)
62. (a) Welshons, W. V.; Murphy, C. S.; Koch, R.; Calaf, G.; Jordan, V. C. Stimulation of breast cancer cells in vitro by the environmental estrogen enterolactone and the phytoestrogen equol. Breast Cancer Res. Treat. 1987, 10 (2), 169-175.
63. (b) Taylor, I.W.; Hodson, P. J.; Green, M. D.; Sutherland, R. L. Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. Cancer Res. 1983, 43, 4007-4010.
64. (c) Jones, P. A.; Baker, V. A.; Irwin, A.; Earl, L. K. Modulation of MCF-7 cell proliferative responses by manipulation of assay conditions. Toxicol. in Vitro 1997, 11, 769-773.
65. (a) Lerner, L. J.; Hilf, R.; Turkheimer, A. R.; Michel, I.; Engel, S. L. Effects of hormone antagonists on morphological and biochemical changes induced by hormonal steroids in the immature rat uterus. Endocrinology 1966, 78, 111-124.
66. (b) Gabbard, R. B.; Hamer, L. F.; Segaloff, A. Structure-activity relationships of four 11-hydroxyestrones isomeric at the C-9 and C-11 positions. Steroids 1981, 37, 243-255. (Pubitemid 11107152)
67. (c) McKim, J. M., Jr.; Wilga, P. C.; Breslin, W. J.; Plotzke, K. P.; Gallavan, R. H.; Meeks, R. G. Potential estrogenic and antiestrogenic activity of the cyclic siloxane octamethylcyclotetrasiloxane (D4) and the linear siloxane hexamethyldisiloxane (HMDS) in immature rats using the uterotrophic assay. Toxicol. Sci. 2001, 63, 37-46.
68. (d) Ashby, J.; Odum, J.; Foster, J. R. Activity of raloxifene in immature and ovariectomized rat uterotrophic assays. Regul. Toxicol. Pharmacol. 1997, 25, 226-231.
69. (e) Ke, H. Z.; Brown, T. A.; Thompson, D. D. Lasofoxifene (CP-336,156), a novel selective estrogen receptor modulator, in preclinical studies. J. Am. Aging Assoc. 2002, 25, 87-99.
70. (f) Riggs, L.; Hartmann, L. C. Selective estrogen-receptor modulators. Mechanisms of action and application to clinical practice. N. Engl. J. Med. 2003, 348, 618-629.
71. (a) Clark, A. J.; Ishi, S.; Richert, N.; Merlino, G. T.; Pastan, I. Epidermal growth factor regulates the expression of its own receptor. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 8374-8378.
72. (b) D'Andrea, M. R.; Derian, C. K.; Leturcq, D.; Baker, S. M.; Brunmark, A.; Ling, P.; Darrow, A. L.; Santulli, R. J.; Brass, L. F.; Andrade- Gordon, P. Characterization of protease activated receptor (PAR-2) immunoreactivity in normal human tissues. J. Histochem. Cytochem. 1998, 46, 157-164.
73. (c) Blesson, C. S.; Awasthi, S.; Kharkwal, G.; Daverey, A.; Dwivedi, A. Modulation of estrogen receptor transactivation and estrogen-induced gene expression by ormeloxifene. A triphenylethylene derivative. Steroids 2006, 71, 993-1000.
74. (d) Lyttle, C. R.; DeSombre, E. R. Uterine peroxidase as a marker for estrogen action. Proc. Natl. Acad. Sci. U.S.A. 1977, 74, 3162-3166.
75. (e) Kym, P. R.; Anstead, G. M.; Pinney, K. G.; Wilson, S. R.; Katzenellenbogen, J. A. Molecular structures, conformational analysis, and preferential modes of binding of 3-aroyl-2 arylbenzo[b]thiophene estrogen receptor ligands: LY117018 and aryl azide photoaffinity labeling analogues. J. Med. Chem. 1993, 36, 3910-3922.
76. (f) Li, X.; Takahashi, M.; Kushida, K.; Inoue, T. The preventive and interventional effects of raloxifene analogue (LY117018 HCl) on osteopenia in ovariectomized rats. J. Bone Miner. Res. 1998, 13, 1005-1010.
77. (g) Curiel, M. D.; Calero, J. A.; Guerrero, R.; Gala, J.; Gazapo, R.; De La Piedra, C. Effects of LY-117018-HCl on bone remodeling and mineral density in the oophorectomized rat. Am. J. Obstet. Gynecol. 1998, 178, 320-325.
78. (h) Jones, C. D.; Jevnikar,M. G.; Pike, A. J.; Peters, M. K.; Black, L. J.; Thompson, A. R.; Falcone, J. F.; Clemens, J. A. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy- 2-(4 hydroxyphenyl)benzo[b]thien-3- yl]-[4-[2-(1-piperidinyl)ethoxy]- phenyl]-methanone hydrochloride (LY 156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J. Med. Chem. 1984, 27, 1057-1066.
79. (i)Wakeling, A. E.;O'Connor,K.M.; Newboult, E. Comparison of the biological effects of tamoxifen and a new antiestrogen (LY 117018) on the immature rat uterus. J. Endocrinol. 1983, 99, 447-453.
80. (a) Frolik, C. A.; Bryant, H. U.; Black, E. C.; Magee, D. E.; Chandrasekhar, S. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. Bone 1996, 18, 621-627. (Pubitemid 26257885)
81. (b) Ma, Y. L.; Bryant, H. U.; Zeng, Q.; Palkowitz, A.; Jee, W. S. S.; Turner, C. H.; Sato, M. Long-termdosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. J. Bone Miner. Res. 2002, 17, 2256-2264.
82. (c) Ke, H. Z.; Brown, T. A.; Thompson, D. D. Lasofoxifene (CP- 336,156), a novel selective estrogen receptor modulator, in preclinical studies. J. Am. Aging Assoc. 2002, 25, 87-99.
83. (d)Walsh, B.W.; Kuller, L. H.; Wild, R. A.; Paul, S.; Farmer, M.; Lawrence, J. B.; Shah, A. S.; Anderson, P. W. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA, J. Am. Med. Assoc. 1998, 279, 1445-1451.
84. (a) Cotreau, M. M.; Stonis, L.; Dykstra, K. H.; Gandhi, T.; Gutierrez, M.; Xu, J.; Park, Y.; Burghart, P. H.; Schwertschlag, U. S. Multiple-dose, safety, pharmacokinetics, and pharmacodynamics of a new selective estrogen receptor modulator, ERA-923, in healthy postmenopausal women. J. Clin. Pharmacol. 2002, 42, 157-165.
85. (b) Baselga, J.; Llombart-Cussac, A.; Bellet, M. Randomised double-blind phase II study of a selective estrogen receptor modulator SERM(LY353381) in patients (pts) with locally advanced or metastatic breast cancer. Breast Cancer Res. Treat. 1999, 57, 31.
86. (c) Buzdar, A. U.; O'Shaughnessy, A.; Hurdis, C.; Booser, D.; Pippen, J.; Jones, S.; Munster, P.; Enas, N.; Melemed, A.; Winer, E.; Storniolo, A. Preliminary results of a randomised double-blind phase II study of the selective estrogen receptor modulator (SERM) arzoxifene (AZ) in patients with locally advanced or metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 2001, 20, 45a.
87. (d) Evans, G.; Bryant, H.; Magee, D.; Sato, M.; Turner, R. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 1994, 134, 2283-2288. (Pubitemid 24142974)
88. (a) Merchenthaler, I. The Effect of estrogens and antiestrogens in rat models of hot flush. Drug Dev. Res. 2006, 66, 182-188.
89. (b) Merchenthaler, I.; Funkhouser, J. M.; Carver, J. M.; Lundeen, S. G.; Ghosh, K.;Winneker, R. C. The effect of estrogens and antiestrogens in a rat model for hot flush. Maturitas 1998, 30, 307-316.
90. (c) Nagamani, M.; Kelver, M. E.; Smith, E. R. Treatment of menopausal hot flashes with transdermal administration of clonidine. Am. J. Obstet. Gynecol. 1987, 156, 561-565.
91. (d) Nomikos, G.; Spyraki, C.; Kazandjian, A.; Sfikakis, A. Estrogen treatment to ovariectomized rats modifies morphine-induced behavior. Pharmacol., Biochem. Behav. 1987, 27, 611-617. (Pubitemid 17132277)
92. (e) Reddy, D. S.; Kulkarni, S. K. Chronic neurosteroid treatment prevents the development of morphine tolerance and attenuates abstinence behavior in mice. Eur. J. Pharmacol. 1997, 337, 19-25.
93. (f) Scott, J. A.; Da Camara, C. C.; Early, J. E. Raloxifene: a selective estrogen receptor modulator. Am. Fam. Physician 1999, 60, 1131-1139.
94. (g) Simpkins, J. W.; Katovich, M. J.; Song, I. C. Similarities between morphine withdrawal in the rat and the menopausal hot flush. Life Sci. 1983, 32, 1957-1966.
95. (h) Speroff, L. Postmenopausal hormone therapy and breast cancer. Obstet. Gynecol. 1996, 87 (Suppl.), 44S-54S.
96. (i) Waldinger, M. D.; Berendsen, H. H.; Schweitzer, D. H. Treatment of hot flushes with mirtazapine: four case reports. Maturitas 2000, 36, 165-168.
97. (j) Whiteman, M. K.; Staropoli, C. A.; Benedict, J. C.; Borgeest, C.; Flaws, J. A. Risk factors for hot flashes in midlife women. J. Women's Health 2003, 12, 459-472.
98. (k) Wren, B. G.; Brown, L. B. A double-blind trial with clonidine and a placebo to treat hot flushes. Med. J. Aust. 1986, 144, 369-370.